Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1257-1261

  Adatia, R ^a   Albini, A ^a   Carlone, S ^a   Giunciuglio, D ^a   Benelli, R ^a   Santi, L ^a   Noonan, D M ^a  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Anti sense DNA; Growth factors; Invasion; Melanoma; Perlecan

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; GROWTH FACTOR; MESSENGER RNA; PERLECAN; PROTEOHEPARAN SULFATE;

ANIMAL CELL; ARTICLE; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE THERAPY; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031462263     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008243115385     Document Type: Article

References (30)

1. Hassell JR, Blochberger TC, Rada JA et al. Proteoglycan gene families. In Kleinman HK (ed): The Extracellular Matrix (Advances in Molecular and Cellular Biology, Vol. 6). Greenwich, CT: JAI Press 1993; 69-113.
2. Noonan DM, Hassell JR. Proteoglycans of basement membranes. In Rohrbach DH.Timpl R (eds): Molecular and Cellular Aspects of Basement Membranes. San Diego, CA: Academic Press 1993; 189-210.
3. Noonan DM, Fulle A, Valente P et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor and the neural cell adhesion molecule. J Biol Chem 1991; 266: 22939-47.
4. Noonan D, Hassel JR. Perlecan, the large low-density proteoglycan of basement membranes: Structure and variant forms. Kidney Int 1993; 43: 53-60.
5. Yayon A, Klagsbrun M, Esko JD et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinty receptor. Cell 1991; 64: 841-8.
6. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705-8.
7. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355-64.
8. Tessler S, Rockwell P, Hicklin D et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994; 289: 12456-61.
9. Aviezer D, Yayon A. Heparin-dependent binding and auto-phosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA 1994; 91: 12173-7.
10. Aviezer D, Hecht D, Safran M et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994; 79: 1005-13.
11. Aviezer D, Levy E, Safran M et al. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem 1994; 269: 114-21.
12. Mali M, Elenius K, Miettinen HM et al. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J Biol Chem 1993; 268: 24215-22.
13. Mali M, Andtfolk H, Miettinen HM et al. Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 1994; 269: 27795-8.
14. Liotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
15. Noonan D, Albini A, Horigan E et al. The basement membrane heparan sulfate proteoglycan: Structure and expression in melanoma cells. Proc AACR 1990; 31: 82.
16. Noonan DM, Horigan E, Ledbetter S et al. Identification of two cDNA clones to the basement membrane proteoglycan. J Biol Chem 1988; 263: 16379-87.
17. Cohen IR, Murdoch AD, Naso MF et al. Abnormal expression of Perlecan proteoglycan in metastatic melanomas. Cancer Res 1994; 54: 5771-4.
18. Aviezer D, Iozzo RV, Noonan DM et al. Suppression of autocrine and paracrine functions of basic Fibroblast Growth Factor by stable expression of Perlecan antisense cDNA. Mol Cell Biol 1997; 17: 1938-46.
19. Halaban R, Kwon BS, Ghosh S et al. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988; 3: 177-86.
20. Gunning P, Leavitt J, Muscat G et al. A human b-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA 1987; 84: 4831-5.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
22. Carmichael J, Degraff WG, Gazdar AF et al. Evaluation of a tetrazolium-based semi-automated colorimetric assay: Assessment of chemotherapy testing. Cancer Res 1987; 47: 936-43.
23. Kleinman HK, McGarvey ML, Hassell JR et al. Basement membranes complexes with biological activity. Biochemistry 1986; 25: 312-8.
24. Albini A, Adelmann-Grill B, Muller PK. Fibroblast chemotaxis. Collagen Rel Res 1985; 5: 283-96.
25. Albini A, Iwamoto Y, Kleinman HK et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
26. Rescan PY, Loreal O, Hassel JR et al. Distribution and origin of the basement membrane component Perlecan in rat liver and primary hepatocyte culture. Am J Pathol 1993; 142:199-208.
27. Nurcombe V, Ford MD, Wildschut JA et al. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 1993; 260: 103-6.
28. Guillonneau X, Tassin J, Berrou E et al. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity. J Cell Physiol 1996; 166: 170-87.
29. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
30. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.